Myt1l haploinsufficiency leads to obesity and multifaceted behavioral alterations in mice.

This was a mouse study, not a human clinical trial, so it does not show how a therapist should treat a patient. The mice did not receive a therapy, so no treatment effect can be inferred. The human MYT1L features mentioned in the paper come from other reports, not from outcomes measured in these mice. Many behavioral outcomes were tested, and the authors state that future confirmatory studies need more conservative statistical approaches. Homozygous Myt1l deletion was lethal by PND 1, so adult behavioral findings apply only to heterozygous mice. Some effects were sex-dependent, and body weight mechanisms such as feeding and metabolism were not measured. The authors note that direct reciprocal social interaction, adult ultrasonic vocalization spectrographic analysis, and broader repetitive behavior measures were not fully assessed.

Funding was from the National Institutes of Health, Simons Foundation Autism Research Initiative, Alexander von Humboldt-Stiftung, and Philipps-Universität Marburg. The paper does not report financial conflicts of interest.

Do not read the mouse behavioral changes as proof of a human treatment or as a complete picture of MYT1L syndrome. This study tested genetically modified mice and did not assess human speech, language, or therapy outcomes.